Skip to main content

Advertisement

Table 2 Response and survival in all 19 patients

From: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Arm Stage ELISPOT response (Y/N/NE) Best response No. of cycles completed Time on trial (months) Months alive from trial start
A M Y SD 8 3.7 9.4
A M N PD 4 1.8 15.9
A M N SD 24 11.1 47.2*
A NED N SD 24 12.4 32.4*
A NED N SD 24 12.2 31.9*
B M Y PD 4 1.9 3.1
B M Y SD 23 12 43.2*
B M Y PD 3 1.4 3.6
B M N SD 22 10 ?*
B M N PD 4 1.8 2.2
B M NE PD 1 0.3 0.4
B M NE PD 4 1.2 1.5
B M NE PD 4 1.8 3.0
C M Y PD 4 1.9 11.3
C LA Y CR 81 39.3 75.4*
C M Y PD 4 1.8 11.0
C M Y SD 12 6.2 48.5*
C M NE PD 3 1.2 2.0
C M NE PD 3 1.4 2.6
  1. Abbreviations: NED = No evidence of disease; M = metastatic; LA = locally advanced; Y = Yes; N = No; NE = not evaluable; * = currently alive; ? = patient is known to be alive but had withdrawn consent; Data as of May 22, 2012.